Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk says Semaglutide approved for long-term weight management in China
02:19am, Tuesday, 25'th Jun 2024
Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.
Novo Nordisk Invests $4.1 Billion For New US Facility—Boosting Ozempic Production
03:42pm, Monday, 24'th Jun 2024
Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company's weight loss and diabetes drugs Wegovy and Ozempic, t
Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing
02:23pm, Monday, 24'th Jun 2024
Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
02:16pm, Monday, 24'th Jun 2024
In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*.
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
02:15pm, Monday, 24'th Jun 2024
Novo Nordisk said it will spend $4.1 billion to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. The investment will fund a new
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
11:40am, Monday, 24'th Jun 2024
Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
Nestle launches 'Ozempic face' range as sales of weight-loss drugs soar
10:53am, Monday, 24'th Jun 2024
Swiss consumer products giant Nestle S.A. (OTC:NSRGF, VTX:NESN)is introducing to help disguise the effect of rapid weight loss brought by the use of drugs such as Novo Nordisk (NYSE:NVO)'s Ozempic a
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
10:05am, Monday, 24'th Jun 2024
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk A/S - share repurchase programme
08:55am, Monday, 24'th Jun 2024
Bagsværd, Denmark, 24 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
7 Strong Buy Blue-Chip Stocks to Keep You in the Green
08:48am, Monday, 24'th Jun 2024
If you are tired of waiting for a rate cut, for the economy to improve and for consumer sentiment to soar so your portfolio turns green, it is best to consider rebalancing it. Several blue-chip stoc
Novo's Wegovy induces higher weight loss in women than men with same heart condition, study shows
04:33pm, Sunday, 23'rd Jun 2024
Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same condition, an analysis of study data published in a medical journal has s
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8
3 Biotech Stocks to Buy Now: June 2024
02:00pm, Friday, 21'st Jun 2024
Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companies s
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
The Best Could Be Yet to Come for Novo Nordisk and Ozempic
08:30am, Friday, 21'st Jun 2024
Novo Nordisk's top-two blockbuster drugs include the same active ingredient -- semaglutide. The company is testing an even higher-dose version of semaglutide, which may yield even better results.
